(IN BRIEF) Novartis has presented new data from the Phase III NATALEE trial at ASCO 2025, showcasing Kisqali’s ability to reduce the risk of recurrence in pre-menopausal patients with high-risk early breast cancer. The data reveals a 33% reduction in … Read the full press release →
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged adjuvant treatment, ASCO 2025, Black patients, Breast Cancer Treatment, CDK4/6 inhibitors, DDFS, disparities in healthcare, early breast cancer, EBC, endocrine therapy, HR+/HER2-, invasive disease-free survival, Kisqali®, metastatic breast cancer, Novartis, Phase III NATALEE, post-menopausal, pre-menopausal, recurrence-free survival, RFS, ribociclib, Risk Reduction, survival benefit